-
Photovoltaic 24
-
Wind energy 6
-
Other renewable energy (nuclear, geothermal, etc.) 22
-
Grid/power transmission 23
-
Energy storage 31
-
Hydrogen energy 10
-
Lithium batteries 48
-
Electric vehicles 45
-
Low-carbon buildings and construction 7
-
Agriculture 11
-
Low-carbon consumer goods 6
-
New materials 22
-
Industrial manufacturing 7
-
Green transportation 22
-
CCUS 2
-
Digital technology for carbon accounting and consulting 22
-
Bio-Tech 2
-
Circular economy 31
All investors
114 institutional investors
Content Filter
-
Photovoltaic 24
-
Wind energy 6
-
Other renewable energy (nuclear, geothermal, etc.) 22
-
Grid/power transmission 23
-
Energy storage 31
-
Hydrogen energy 10
-
Lithium batteries 48
-
Electric vehicles 45
-
Low-carbon buildings and construction 7
-
Agriculture 11
-
Low-carbon consumer goods 6
-
New materials 22
-
Industrial manufacturing 7
-
Green transportation 22
-
CCUS 2
-
Digital technology for carbon accounting and consulting 22
-
Bio-Tech 2
-
Circular economy 31
-
Frees Fund
- Investments: 312
- Funds: 14
- Shanghai
-
Lithium batteries
-
Low-carbon consumer goods
-
Green transportation
-
Circular economy
Frees Fund is committed to making future-oriented investment, so it has become the first-round institutional investor of many forward-looking enterprises with original innovation ability. Consumption and TMT, high technology and biomedicine are the three major investment directions of Frees Fund. Frees Fund has invested in more than 150 innovative enterprises, covering lifestyle, culture and entertainment, finance, intelligent manufacturing, artificial intelligence, biotechnology and new drug research and development, new energy and new materials, and so on. Frees' portfolio not only includes Three Squirrels, 360 DigiTech, Uber Global, Unity and other listed companies, but also many innovative enterprises with high growth, including Qingtao Development, Xtaipi, Patpat, Coyote Bio, Robot Phoenix, Saturnbird Coffee, Pyrotech Therapeutics and so on.
-
CAS Investment
- Investments: 152
- Funds: 15
- Beijing
-
Grid/power transmission
-
New materials
CAS Investment Management Co., Ltd. (abbreviated as CASI)' s controlling shareholder is Chinese Academy of Sciences Holdings Co., Ltd. and has State-owned Assets Supervision and Administration Commission of the State Council and an employee-owned company as shareholders. Its predecessor is the Chinese National Economic Council-CAS Scientific and Technological Promotion & Economic Development Foundation. In 1993, it set up China Scientific and Technological Promotion Investment Company in line with Chinese policies governing foundations. In 2006, it was restructured into a limited liability company and changed to its present name. The key industries invested by CASI include instrumentation and high-end equipment manufacturing, information technology, pharmaceutical chemical industry and new materials, modern service industry, etc., and the company have successively supported more than 300 industrialization projects of scientific and technological achievements. CASI is committed to becoming a leading private equity fund manager in China.
-
DCP Capital
- Investments: 22
- Funds: 7
- Zhuhai, Guangdong Province
-
Lithium batteries
-
Other renewable energy (nuclear, geothermal, etc.)
DCP is an international private equity investment institution focusing on the Greater China market. In the past 30 years, DCP team has invested in a series of pioneering projects in China's PE industry, and supported many leading Chinese enterprises, such as Ping an, Mengniu Dairy, Haier, CICC, Venus Medtech, Tonghua Dongbao, Oriental Yuhong, Simple Love, Nanfu Battery, COFCO Meat, Sunner Development, Far East Horizon, Hotwon, Hengan Group, Belle International, Modern Farming, etc. With its international investment experience and localized resource networks, DCP has accumulated profound industry expertise and solid post-investment management abilities. Adhering to the concept of value investment, DCP aims to establish a long-term win-win partnership with the invested enterprises and create value for the long-term development of the invested enterprises.
-
Hankang Capital
- Investments: 75
- Funds: 13
- Shanghai
-
Photovoltaic
-
Grid/power transmission
-
Digital technology for carbon accounting and consulting
Hankang Capital (formerly "Shanghai Jianxin Capital") is a venture capital focusing on the biomedical industry. We pay attention to major diseases and major clinical needs, carry out in-depth research, support pioneering companies with first-class team and technology platform in advance, and provide professional insights, experience and resources in product pipeline, team building, application and registration, clinical trials, etc. to promote them to become leading enterprises in the industry as soon as possible. We have invested in Innocare Pharma Limited, Akeso, Chip Screen, Keymed Biosciences, AbbiskoTherapeutics and other industry leading companies. Hankang Capital has won the honors such as "TOP 100 Venture Capital Institutions", "TOP 20 Healthcare Investment Institutions", and "TOP 50 Venture Capital Institutions Recognized by LP in China" for many times.
-
GOBI China
- Investments: 279
- Funds: 11
- Shanghai
-
Digital technology for carbon accounting and consulting
Founded in 2002, Gobi China is a leading venture capital firm in China. As a global-minded VC, Gobi China manages multiple funds denominated in both US Dollar and Renminbi. Gobi China has invested in over 300 portfolio companies across China and other parts of the world, and has created over RMB 2 billion cash return for its Limited Partners to date. Gobi’s notable portfolio companies include Tuniu.com, 36Kr, Teambition, Dianwoda, Madhouse, Opzoon, Urban Revivo, WaveOptics, Airwallex, Megarobo, eSign, VirtAI, Brite Semiconductor, DTStack, Chuangkit, Timecho, KeyFunc, Zhiketong, Cloudwise, Yoyi Digital, etc. Gobi China will continue to pay attention to value investment opportunities in deep technology, corporate services, new energy and other fields.